THOMAS WILLIAM EVANS
Occupational Therapy in San Diego, CA

2006002, Feb 2, 2006

May 18, 2005

11/131479

Catherine Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary Wloch - San Diego CA, US
Thomas Evans - San Diego CA, US
Andrew Geall - San Marcos CA, US
Gretchen Jimenez - San Diego CA, US

C12Q 1/70, C07H 21/04, C12P 21/06, A61K 39/145, C07K 14/11

435005000, 435069100, 435456000, 435325000, 424209100, 530350000, 536023720

The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.

2010019, Aug 5, 2010

Jan 15, 2010

12/688614

Catherine J. Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US

Vical Incorporated - San Diego CA

A61K 31/7052, C07H 21/00, C12N 15/63, A61P 31/12, A61P 37/04

514 44 R, 536 231, 4353201

The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.

8128938, Mar 6, 2012

Aug 17, 2007

11/892016

Catherine J. Luke - Rockville MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US

Vical Incorporated - San Diego CA

A61K 39/145, A61K 31/7088, C12N 15/44, C12N 15/36

4242091, 514 44 R, 536 2372, 4353201

The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.

2012012, May 24, 2012

Sep 30, 2011

13/250508

Catherine J. LUKE - Frederick MA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San marcos CA, US
Gretchen S. Jimenez - San Diego CA, US

Vical Incorporated - San Diego CA

A61K 39/145, C12N 15/63, A61P 31/16, C12N 15/44, C12N 15/51

4242091, 536 2372, 4353201

The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.